ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Novartis' oral therapy iptacopan shows promise in PNH
June 16, 2021Novartis has revealed new positive data for its investigational treatment iptacopan as a monotherapy treatment for patients with the rare blood disorder paroxysmal nocturnal hemoglobinuria (PNH). -
Novartis Announces Iptacopan Met Primary Endpoint in Rare Kidney Disease IgA Nephropathy
June 09, 2021Novartis announced Phase II primary endpoint data showing investigational iptacopan (LNP023) – a first-in-class, oral, targeted factor B inhibitor – reduced protein in the urine (proteinuria), an increasingly recognized surrogate marker correlating ... -
Novartis’ rare renal disease candidate shows promise in phase II
October 29, 2020Interim analysis results for Novartis’ rare renal disease candidate iptacopan proved promising in a phase II study of the investigational drug.
Pharma Sources Insight January 2025
